Mode
Text Size
Log in / Sign up
N/A N=220 Treatment

The Closer Trial: A Safety and Efficacy Study of the Rex Medical Vascular Sealing System

Surgical Wound

Enrolled (actual)
220
Serious AEs
0.0%
Results posted
Dec 2016
Primary outcome: Primary: Time to Hemostasis — 1.78 minutes

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Closer VSS (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Rex Medical
Primary completion
Feb 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to Hemostasis
1.78
PRIMARY
Rate of Combined Major Access Site Closure-related Complications
SECONDARY
Time to Ambulation
2.50
SECONDARY
Time to Discharge Eligibility
2.83
SECONDARY
Time to Hospital Discharge
13.12
SECONDARY
Device Success
216
SECONDARY
Rate of Combined Minor Access Site Closure-related Complications
3
SECONDARY
Procedure Success
219

Summary

The objective of this trial is to demonstrate the safety and effectiveness of the Rex Medical Closer Vascular Sealing System in sealing femoral arterial access sites.

Eligibility Criteria

Inclusion Criteria

Pre-Op Inclusion Criteria:

1 - Acceptable candidates for an elective, non-emergent diagnostic or interventional endovascular procedure via the common femoral artery using a 5, 6, or 7 Fr introducer sheath.

-

Exclusion Criteria

Pre-Operative Exclusion Criteria:

  • - Significant bleeding diatheses or coagulopathy
  • - Planned endovascular or surgical procedures within next 30 days
  • - Planned ipsilateral femoral arteriotomy within next 90 days
  • - Arteriotomy in ipsilateral groin within the past 30 days with any residual hematoma, significant bruising or vascular complication
  • - Previous vessel closure device used in ipsilateral groin within the past 90 days
  • - Previous vascular surgery or repair in the vicinity of the target access site
  • - Severe peripheral vascular disease in the ipsilateral limb requiring surgical or endovascular treatment within the pervious 30 days or next 30 days
  • - Existing nerve damage in ipsilateral limb
  • - Extreme morbid obesity (BMI > 4 kg/m2)

Intra-operative Exclusion Criteria:

  • - Use of a procedural sheath that is 7 Fr
  • - Difficult insertion of procedural sheath or needle stick problems at the onset of the procedure
  • - Placement of an ipsilateral venous sheath for procedure
  • - Procedural sheath placement either through the superficial femoral artery and into the profunda femoris artery, or placement at or distal to bifurcation of the superficial femoral artery and the profunda femoris artery
  • - In subjects receiving unfractionated heparin, an ACT > 350 seconds, or > 250 seconds in the presence of a GP IIb/IIIa inhibitor
  • - Procedures or existing medical conditions that may extend index hospitalization beyond 24 hours post-procedure
  • - Systemic hypertension (SBP > 180 mmHg) or hypotension (SBP < 90 mmHg) just prior to enrollment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02136004). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search